Neuren Pharmaceuticals Reports Record Sales Growth for Rett Syndrome Drug

2 min read | February 27, 2025 12:21 PM AEDT | By Team Kalkine Media

Google News:

Neuren Pharmaceuticals Reports Record Sales Growth for Rett Syndrome Drug — Image source: shutterstock

Recent News

The Insider Moves That Didn't Pay Off: What MetalsTech's Latest Share...

Beyond the AI Hype: Two ASX ETFs Riding the Next Technology Wave

Can ReadCloud's Push Toward Profitability Change Its Market Story?

Three ASX Heavyweights Still Winning Attention in June

Make Kalkine Media
My Trusted Source

Highlights

Neuren Pharmaceuticals (NEU) sees a 97% surge in full-year sales for Rett syndrome drug DAYBUE™.

Acadia Pharmaceuticals (NASDAQ:ACAD) reports record quarterly and full-year sales in the US.

Forecasted royalties for Neuren Pharmaceuticals set to jump 110% in 2024.

Neuren Pharmaceuticals (ASX:NEU) has posted a remarkable sales performance for its Rett syndrome treatment, DAYBUE™, marking a significant milestone in its commercial journey. The company reported a 97% increase in full-year net sales, demonstrating strong market demand and a growing patient base.

Its US development partner, Acadia Pharmaceuticals (NASDAQ:ACAD), recorded full-year sales of $US348.4 million, reaching the upper range of its sales forecast. The fourth quarter alone brought in $US96.7 million, making it the strongest quarter since the product’s launch in April 2023.

With 70% of the 5,500 to 5,800 diagnosed Rett syndrome patients in the US yet to try DAYBUE™, Neuren Pharmaceuticals sees substantial potential for continued expansion. As a result, the company projects royalties of $56.2 million for 2024, reflecting a 110% increase from the previous year.

The performance of DAYBUE™ highlights the growing recognition and adoption of the therapy within the Rett syndrome community. The treatment, which has been the first FDA-approved option for this rare neurological disorder, has seen a steady increase in prescriptions as awareness among healthcare professionals and caregivers expands.

Industry analysts have noted that DAYBUE™'s strong momentum in the US market is a testament to the significant unmet need in Rett syndrome treatment. With further outreach and education, more patients are expected to benefit from this therapy in the coming years.

The company’s revenue outlook for 2024 suggests further scaling opportunities, potentially reinforcing Neuren Pharmaceuticals' position in the biopharmaceutical market. With continued efforts in commercial expansion and research, the company remains focused on bringing innovative treatments to more patients worldwide.

The record-breaking sales figures underscore the impact of DAYBUE™ in addressing a critical medical need, positioning Neuren Pharmaceuticals for further growth in the rare disease treatment space.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.